Low morbidity and mortality with COVID‐19 in sickle cell disease: A single center experience
Abstract Coronavirus disease 2019 (COVID‐19) is caused by SARS‐CoV‐2 infection, which evolved into a global pandemic within a short time. Individuals with sickle cell disease (SCD) suffer from underlying cardiopulmonary comorbidities and are at risk of severe complications such as pneumonia, acute c...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-11-01
|
| Series: | eJHaem |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jha2.87 |
| _version_ | 1797739941922340864 |
|---|---|
| author | Preethi Ramachandran Abhilash Perisetti Balachandar Kathirvelu Mahesh Gajendran Snigdha Ghanta Ifeanyichkwu Onukogu Ted Lao Faiz Anwer |
| author_facet | Preethi Ramachandran Abhilash Perisetti Balachandar Kathirvelu Mahesh Gajendran Snigdha Ghanta Ifeanyichkwu Onukogu Ted Lao Faiz Anwer |
| author_sort | Preethi Ramachandran |
| collection | DOAJ |
| description | Abstract Coronavirus disease 2019 (COVID‐19) is caused by SARS‐CoV‐2 infection, which evolved into a global pandemic within a short time. Individuals with sickle cell disease (SCD) suffer from underlying cardiopulmonary comorbidities and are at risk of severe complications such as pneumonia, acute chest syndrome, thrombosis, stroke, and multiorgan failure. Whether COVID‐19 poses a high risk of morbidity and mortality in SCD patients remains unclear. Patients with SCD and COVID‐19 can present with overlapping clinical features such as respiratory symptoms with ground‐glass infiltrates, hyperinflammatory state, and increased risk of thromboembolism. This highlights the need to maintain a low threshold for testing for COVID‐19 infection among symptomatic and hospitalized SCD patients. We report a case series of nine hospitalized SCD patients diagnosed with COVID‐19 from March 18, 2020 to April 30, 2020 at a tertiary medical center in New York City. The mean age of the study population was 27.9 years, and interval since onset of symptoms and hospital presentation was 1–2 weeks. All patients in our series improved and were discharged home. This limited study shows that SCD patients, who are perceived to be high risk, maybe somehow protected from severe symptoms and complications of COVID‐19 infection. |
| first_indexed | 2024-03-12T14:05:25Z |
| format | Article |
| id | doaj.art-15f08552ddd842398e4837c569b54c91 |
| institution | Directory Open Access Journal |
| issn | 2688-6146 |
| language | English |
| last_indexed | 2024-03-12T14:05:25Z |
| publishDate | 2020-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | eJHaem |
| spelling | doaj.art-15f08552ddd842398e4837c569b54c912023-08-21T14:10:57ZengWileyeJHaem2688-61462020-11-011260861410.1002/jha2.87Low morbidity and mortality with COVID‐19 in sickle cell disease: A single center experiencePreethi Ramachandran0Abhilash Perisetti1Balachandar Kathirvelu2Mahesh Gajendran3Snigdha Ghanta4Ifeanyichkwu Onukogu5Ted Lao6Faiz Anwer7Department of Hematology and Oncology Brookdale University Hospital and Medical Center Brooklyn New YorkDivision of Gastroenterology and Hepatology University of Arkansas for Medical Sciences Little Rock ArkansasDepartment of Rehabilitation Sciences The University of Texas at El Paso El Paso TexasDepartment of Internal Medicine Texas Tech University Health Sciences Center El Paso Paul L Foster School of Medicine El Paso TexasDepartment of Internal Medicine Brookdale University Hospital and Medical Center Brooklyn New YorkDepartment of Internal Medicine Brookdale University Hospital and Medical Center Brooklyn New YorkDepartment of Internal Medicine Brookdale University Hospital and Medical Center Brooklyn New YorkDepartment of Hematology/Oncology Stem Cell Transplantation Cleveland Clinic Cleveland OhioAbstract Coronavirus disease 2019 (COVID‐19) is caused by SARS‐CoV‐2 infection, which evolved into a global pandemic within a short time. Individuals with sickle cell disease (SCD) suffer from underlying cardiopulmonary comorbidities and are at risk of severe complications such as pneumonia, acute chest syndrome, thrombosis, stroke, and multiorgan failure. Whether COVID‐19 poses a high risk of morbidity and mortality in SCD patients remains unclear. Patients with SCD and COVID‐19 can present with overlapping clinical features such as respiratory symptoms with ground‐glass infiltrates, hyperinflammatory state, and increased risk of thromboembolism. This highlights the need to maintain a low threshold for testing for COVID‐19 infection among symptomatic and hospitalized SCD patients. We report a case series of nine hospitalized SCD patients diagnosed with COVID‐19 from March 18, 2020 to April 30, 2020 at a tertiary medical center in New York City. The mean age of the study population was 27.9 years, and interval since onset of symptoms and hospital presentation was 1–2 weeks. All patients in our series improved and were discharged home. This limited study shows that SCD patients, who are perceived to be high risk, maybe somehow protected from severe symptoms and complications of COVID‐19 infection.https://doi.org/10.1002/jha2.87anemiageneral hematologyhematological oncologyhemoglobin disorderssickle cell disease |
| spellingShingle | Preethi Ramachandran Abhilash Perisetti Balachandar Kathirvelu Mahesh Gajendran Snigdha Ghanta Ifeanyichkwu Onukogu Ted Lao Faiz Anwer Low morbidity and mortality with COVID‐19 in sickle cell disease: A single center experience eJHaem anemia general hematology hematological oncology hemoglobin disorders sickle cell disease |
| title | Low morbidity and mortality with COVID‐19 in sickle cell disease: A single center experience |
| title_full | Low morbidity and mortality with COVID‐19 in sickle cell disease: A single center experience |
| title_fullStr | Low morbidity and mortality with COVID‐19 in sickle cell disease: A single center experience |
| title_full_unstemmed | Low morbidity and mortality with COVID‐19 in sickle cell disease: A single center experience |
| title_short | Low morbidity and mortality with COVID‐19 in sickle cell disease: A single center experience |
| title_sort | low morbidity and mortality with covid 19 in sickle cell disease a single center experience |
| topic | anemia general hematology hematological oncology hemoglobin disorders sickle cell disease |
| url | https://doi.org/10.1002/jha2.87 |
| work_keys_str_mv | AT preethiramachandran lowmorbidityandmortalitywithcovid19insicklecelldiseaseasinglecenterexperience AT abhilashperisetti lowmorbidityandmortalitywithcovid19insicklecelldiseaseasinglecenterexperience AT balachandarkathirvelu lowmorbidityandmortalitywithcovid19insicklecelldiseaseasinglecenterexperience AT maheshgajendran lowmorbidityandmortalitywithcovid19insicklecelldiseaseasinglecenterexperience AT snigdhaghanta lowmorbidityandmortalitywithcovid19insicklecelldiseaseasinglecenterexperience AT ifeanyichkwuonukogu lowmorbidityandmortalitywithcovid19insicklecelldiseaseasinglecenterexperience AT tedlao lowmorbidityandmortalitywithcovid19insicklecelldiseaseasinglecenterexperience AT faizanwer lowmorbidityandmortalitywithcovid19insicklecelldiseaseasinglecenterexperience |